Home ›
Endometrial Cancer Uterine Cancer Trials ›
NCT06584032
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
Trial Details
NCT ID NCT06584032
Phase PHASE3
Sponsor Hutchmed
Status RECRUITING
Cancer Type Endometrial Cancer Uterine Cancer
Interventions fruquintinib sintilimab paclitaxel doxorubicin
Locations (sample) Beijing, Beijing Municipality, China|39.9075,116.39723 Chongqing, Chongqing Municipality, China|29.56026,106.55771 Fuzhou, Fujian, China|26.06139,119.30611 Guangzhou, Guangdong, China|23.11667,113.25 Nanning, Guangxi, China|22.81667,108.31667
Key Eligibility Criteria
Have fully understood and voluntarily signed the informed consent form Age 18 to 75 years (inclusive) ; Body mass index (BMI) ≥ 18.5kg/m\^2; Histologically or cytologically confirmed advanced or recurrent endometrial cancer with measurable lesions Patients who previously failed first-line systemic platinum-based therapy
For full eligibility, visit ClinicalTrials.gov .